ArticleProtein and peptide letters2025
Effect of Adipokinetic Hormone on Learning-Memory in a Scopolamine-Induced Alzheimer's Model in Mice.
Article in Protein and peptide letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionNeurosecretory cells of insects synthesize Adipokinetic Hormone (AKH). Previous studies indicated that AKH improves memory functions. This study aimed to explore the effects of AKH on learning and memory in an Alzheimer's disease model.
methodsMorris Water Maze (MWM), Passive Avoidance (PA), and Modified Elevated Plus Maze (mEPM) tests were conducted in BALB/c mice. Initially, each group consisted of 8 to 9 animals; in total, 120 animals were used in this study. The groups included control, Ani-AKH (1 and 2 mg/kg), Lia-AKH (1 and 2 mg/kg), Pht-HrTH (1 and 2 mg/kg), Scopolamine (1 mg/kg), and Scopolamine combinations. Hormones were given for 6 days in the MWM test to evaluate learning and memory before the second trial in the PA test for memory assessment and after the first trial in the mEPM test to examine consolidation.
resultsIn the MWM test, Ani-AKH and Pht-HrTH reduced escape latency compared to the scopolamine group (p<0.05). During the probe trial, Ani-AKH increased time in the escape platform quadrant (p<0.5) and reversed scopolamine's effects (p<0.001). Lia-AKH and Pht-HrTh did not affect time in the quadrant but reversed scopolamine's effects (p<0.01). In the PA test, Ani- AKH reversed scopolamine's effects (p<0.5), while Lia-AKH did so in the mEPM test (p<0.01). The control group showed strong muscarinic receptor staining, while the scopolamine group did not. Ani-AKH and Lia-AKH showed moderate to strong receptor staining, indicating partial restoration. DISCUSSION: AKH and its analogs may enhance memory function by modulating cholinergic pathways, particularly through the partial restoration of muscarinic receptor activity. These results underscore their potential as investigational therapeutics for neurodegenerative disorders characterized by cognitive decline.
conclusionOur study indicates that AKH may help reduce memory impairments, though the effects depend on the specific assessment methods used in the tests.
Indexed as
Identifiers
40588998What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.